Figure 5
From: eNAMPT neutralization reduces preclinical ARDS severity via rectified NFkB and Akt/mTORC2 signaling
eNAMPT neutralization attenuates plasma biomarker increases in preclinical rat and porcine models of acute lung injury. (A) Plasma biomarker levels of eNAMPT, IL-6, and TNFα were measured (MesoScale Discovery platform) in control rats (n = 5) and at the conclusion of LPS-challenged rat experiments (18 h, n > 6 each group). The eNAMPT-neutralizing mAb markedly reduced plasma levels of each protein (*p < 0.05 control vs. untreated LPS; **p < 0.05 mAb LPS vs. untreated LPS). (B) Plasma biomarker levels of eNAMPT, IL-6 and TNFα measured in control rats (n = 5) and at the conclusion of ARDS/VILI-challenged rat experiments (n > 6 each group). The eNAMPT-neutralizing mAb markedly reduced plasma levels of each protein (*p < 0.05 control vs. untreated LPS/VILI; **p < 0.05 mAb LPS/VILI vs. untreated LPS/VILI). (C) Plasma levels of eNAMPT, IL-6, IL-1RA, and angiopoetin-2 were determined at time 0 and at 12 h in the porcine model of septic shock/VILI with significant increases in each protein at 12 h. With the exception of IL-1RA, the eNAMPT-neutralizing mAb markedly reduced LPS/VILI-induced elevations at 12 (*p < 0.05 control vs. untreated LPS/VILI; **p < 0.05 mAb LPS/VILI vs. untreated LPS/VILI).
